Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Yale on monkeypox: What you need to know

As the number of monkeypox cases continues to rise around the world—and in the United States—public health officials are increasingly advising the public to be...

| By Kelley Gipson

How our immune system recognizes pathogens

UConn Health immunology researcher Jianbin Ruan uses high tech tools such as cryo-electron microscopy and x-ray crystallography to study how certain pathogens can escape our immune...

| By Kelley Gipson

How gut microbes evolve and become dangerous

Gut microbes have been linked to both good health and the promotion of diseases such as autoimmune disorders, inflammatory bowel diseases, metabolic syndrome, and even...

| By Kelley Gipson

Weekly Roundup – July 14, 2022 

View this email in your browser Weekly Roundup – July 14, 2022  Now in its 15th year, the Marcum LLP Tech Top 40 is the premier awards program...

| By Kelley Gipson

Study finds hospital adverse events decrease

The largest medical record-based study ever of adverse events suffered by hospitalized patients in the U.S. reports a significant decrease in the rate of such...

| By Kelley Gipson

Yale ‘blockchain’ offers control over genome

Blockchain is a digital technology that allows a secure and decentralized record of transactions that is increasingly used for everything from cryptocurrencies to artwork. But...

| By Kelley Gipson

Ireland’s Nuritas chooses New Haven HQ location

Ireland-based Nuritas is establishing its North American headquarters in New Haven. The move is evidence of the growing appeal of the Elm City’s thriving bioscience ecosystem. Nuritas...

| By Kelley Gipson

Developers to spend $300 million on Science Park

Science Park is an 80-acre swath of former industrial land in the central Newhallville neighborhood of New Haven. Evolving over the decades from factories to industrial...

| By Kelley Gipson

Boehringer and allies to build anti-superbug startup

Boehringer Ingelheim is pumping 30 million euros ($31 million) into the fight against drug-resistant bacteria. Working with Evotec and bioMérieux, the German drugmaker has set up...

| By Kelley Gipson

Weekly Roundup – July 7, 2022 

View this email in your browser Weekly Roundup – July 7, 2022  Michael Kasdan, Partner at Wiggin and Dana, recently published an article The Patent vs Trade...